About "Pharmaceuticals & life science"

The PwC pharmaceuticals and life science practice provides professional services to leading pharmaceuticals and life science organizations.

Article archive

• Webcast

  Why Unique Device Identification (UDI) and what lies ahead for the medtech industry? webcast – June 6, 2013
  

  5/14/13 | Pharmaceuticals & life science

  Please join us for a webcast featuring Jay Crowley from FDA and Jeffrey Secunda from AdvaMed as featured speakers. During this webcast, Jay and Jeffrey will provide their perspectives on the future of UDI in the medical device industry.

• Medical device excise tax (updated March 28, 2013)
  

  3/29/13 | Pharmaceuticals & life science

  This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that medical device manufacturers will need to begin accounting for this tax for all sales, other than tax free sales, beginning January 1, 2013 and will need to consider the impact of this tax on their 2013 results.

• New tax law extends research & development tax credit
  

  2/11/13 | Pharmaceuticals & life science

  This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that the new tax law extends research & development tax credit and provides guidance on accounting for the retroactive reinstatement of the R&D tax credit.

• Webcast

  CMS Shines the Light on the Transparency Final Rule: Insight & Implications webcast – February 12, 2013
  

  2/7/13 | Pharmaceuticals & life science

  The Center for Medicare & Medicaid Services (CMS) released the highly anticipated Final Rule implementing the physician payment sunshine provisions on Section 6002 of the Affordable Care Act. PwC provides a summary of the key provisions of the Final Rule as well as a facilitated discussion about the impact of the provisions on the industry’s efforts to develop, implement and maintain the processes and systems necessary to comply with the law.

• Webcast

  Conflict minerals: What does Dodd-Frank Section 1502 mean for companies in the Life Sciences industry? – February 6, 2013
  

  1/25/13 | Pharmaceuticals & life science

  On August 22, 2012 the SEC issued a final rule on conflict minerals pursuant to Dodd-Frank Section 1502. Join us as PwC panelists from our Health Industries practice lead a discussion addressing the rule, what life sciences products are likely to be covered, and what companies should be doing now.

• Webcast

  From vision to decision - Pharma 2020 webcast - December 6, 2012
  

  11/26/12 | Pharmaceuticals & life science

  Many of the conditions that will determine what happens in 2020 are already in place. Most of the products to be launched are already in the pipeline; development processes are similar to those used over the past 10 years; a demanding commercial environment looks set to continue; and the prevailing management culture remains that of the late twentieth century. A more flexible and adaptive model must be adopted.

• Emerging mHealth: Paths for growth
  

  6/7/12 | Pharmaceuticals & life science

  PwC report shows developed and emerging markets see mHealth's potential to transform healthcare innovation, but resistance to change could be a barrier.

• Potential Accounting Implications of Supreme Court Decision on the Affordable Care Act
  

  5/31/12 | Pharmaceuticals & life science

  The Supreme Court heard arguments concerning the Affordable Care Act in March 2012 and expects to issue its decision on the constitutionality of the Affordable Care Act by the end of June 2012. If the law should be invalidated by the Supreme Court, either in whole or in part, there could be significant accounting and financial reporting implications. This PwC Pharmaceutical and Life Sciences Industry Alert focuses on the potential accounting implications of the Supreme Court decision on the Affordable Care Act.

• Greece Debt Restructuring
  

  4/9/12 | Pharmaceuticals & life science

  In February 2012, the Greek government announced a debt restructuring which required holders to exchange their two-year and three-year bonds, currently scheduled to mature in December 2012 and 2013, for new non-interest bearing government bonds with longer maturities and a reduced redemption value. This edition of PwC's Pharmaceutical and Life Sciences Industry Alert discusses why pharmaceutical companies will need to evaluate the debt restructuring in order to properly assess the accounting impact of this event.

• European Economic Environment - US GAAP Accounting Considerations
  

  1/11/12 | Pharmaceuticals & life science

  There continues to be significant economic problems in some European countries that are members of the single currency (the Euro zone) as well as potential uncertainty about the single currency itself. This Pharma and Life Sciences Alert discusses why austerity programs aimed at reducing debt levels in these countries have not eliminated the possibility that some European countries could default on sovereign debt and other governmental obligations.

• Accounting for the Annual Pharmaceutical Fee
  

  4/21/11 | Pharmaceuticals & life science

  This Pharma and Life Sciences Alert is on the annual pharmaceutical fee which provides reminders on the key provisions of the fee and also includes a discussion on several proposed changes that may impact a company's accounting in 2011.

• MoneyTree: High-dollar deals
  

  6/29/10 | Pharmaceuticals & life science

  Life sciences venture capital falls short of strong second-quarter performance, but year-over-year trend remains positive.